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What are they? Cannabinoid
receptors are G protein-
coupled receptors with 7 trans-
membrane domains. They are
expressed on the cell surface
with their binding domain
exposed to the extracellular
space. To date, two
cannabinoid receptors have
been cloned, CB1 and CB2.
Recent evidence suggests that
a third ‘CB3’ receptor is out
there, waiting to be cloned.
Where are they? CB1
receptors are found in many
brain regions including cortex,
hippocampus, nucleus
accumbens, basal ganglia,
hypothalamus, amygdala,
cerebellum and retina. CB2 is
localized to immune system
cells. Experiments in the
hippocampus suggest that
‘CB3’ is there, but the presence
or absence of ‘CB3’ in other
brain regions remains to be
determined.
What turns them on? ∆9-
tetrahydrocannabinol (THC), one
of the psychoactive ingredients
in marijuana, does a pretty good
job, but more potent agonists
such as the synthetic compound
WIN55,212-2 (WIN), are
available. Endocannabinoids
also bind and activate
cannabinoid receptors.
What are endocannabinoids?
THC and WIN are examples of
exogenous cannabinoid
receptor ligands, but the body
makes its own ligands, too, and
these are referred to as
endocannabinoids. Two of the
best-characterized endo-
cannabinoids are anandamide
and 2-arachidonylglycerol (2-
AG). Other candidate endo-
cannabinoids have been
identified but which, if any, of
these compounds are
physiologically relevant
cannabinoid receptor ligands is
still an open question.
Events downstream of
cannabinoid receptors... Like
other G protein-coupled
receptors, binding of ligand to
cannabinoid receptors causes
dissociation of the α and βγ G
protein subunits from the
cannabinoid receptor and from
each other. Release of the α
subunit leads to inhibition of
adenylyl cyclase, reducing
cAMP levels in the cell. In
neurons dissociated βγ subunits
directly inhibit calcium channels
that control neurotransmitter
release. Effects on other ion
channels have also been
reported. In addition, there is
evidence of a direct inhibitory
effect on the transmitter release
machinery.
When do they get activated?
Endocannabinoids are released
in a calcium-dependent manner
from dendrites, and maybe
other parts of the cell, when
neurons are activated. Endo-
cannabinoids then travel
backwards across the synaptic
cleft, acting as retrograde
messengers at cannabinoid
receptors that are present on
nearby presynaptic axon
terminals.
What effect does this have?
Action potential-evoked
neurotransmitter release is
suppressed when cannabinoid
receptors are activated. In the
hippocampus, axon terminals
that release inhibitory neuro-
transmitter are much more
sensitive to endocannabinoids
than terminals that release
excitatory neurotransmitter, so
moderate neuronal activity
may preferentially reduce
inhibitory input, while stronger
activity could suppress both
excitatory and inhibitory
inputs. In the cerebellum,
excitatory and inhibitory inputs
seem to have about the same
sensitivity to
endocannabinoids.
What happens if we don’t
have them? We don’t know
what happens in humans, but
mice that have no CB1
receptors have improved
memory, decreased appetite, a
decreased tendency to become
addicted to opiates, an
increased sensitivity to pain,
reduced locomotor activity, and
shorter life spans than normal
mice, suggesting a role for
endocannabinoids in each of
these systems.
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Figure 1. Depolarization of a postsynap-
tic neuron releases endocannabinoids.
Binding of ligand to the CB1 receptor
causes dissociation of the α and βγ sub-
units (red) of the G protein that is
coupled to the receptor. The α subunit
inhibits adenylate cyclase while the βγ
subunits inhibit voltage-dependent
calcium channels (pink) that control
release of neurotransmitter-filled vesi-
cles (yellow).
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